BING Z CARTER to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications BING Z CARTER has written about Xenograft Model Antitumor Assays.
Connection Strength
0.468
-
Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia. Mol Cancer Ther. 2020 08; 19(8):1636-1648.
Score: 0.095
-
An ARC-Regulated IL1?/Cox-2/PGE2/?-Catenin/ARC Circuit Controls Leukemia-Microenvironment Interactions and Confers Drug Resistance in AML. Cancer Res. 2019 03 15; 79(6):1165-1177.
Score: 0.087
-
Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res. 2018 05 15; 24(10):2417-2429.
Score: 0.082
-
Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther. 2017 06; 16(6):1133-1144.
Score: 0.077
-
Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NF?B/IL1? signaling network. Oncotarget. 2016 Apr 12; 7(15):20054-67.
Score: 0.072
-
Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway. Cell Death Dis. 2020 07 22; 11(7):555.
Score: 0.024
-
miR-150 exerts antileukemia activity in vitro and in vivo through regulating genes in multiple pathways. Cell Death Dis. 2016 09 22; 7(9):e2371.
Score: 0.019
-
Dasatinib induces autophagic cell death in human ovarian cancer. Cancer. 2010 Nov 01; 116(21):4980-90.
Score: 0.012